Citing a (most likely rare) positive impact from COVID-19, GenMark Diagnostics (NASDAQ:GNMK) sees Q1 revenue of ~$38.7M, up about 80% from a year ago and 46% above consensus of $26.5M.
About 80% of gross ePlex placements (net of 54 in
the quarter) were from customers interested in COVID-19 testing.
SARS-CoV-2 consumables accounted for ~2% of total ePlex revenue.
2020 revenue guidance increased to $112M – 122M from $100M – 110M.
Management will provide another update during its earnings call next month.
Shares up 29% after hours.
https://seekingalpha.com/news/3559147-genmark-q1-revenue-up-big-on-covidminus-19-boost-shares-up-29-after-hours
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.